Before joining Biogen, Ms. Karaboutis was CIO at Dell Inc. She’s also held global IT and operations positions at Ford Motor Co. and General Motors Co.

Her exit comes less than a year after the departure of another IT executive and a broader executive shuffle at Biogen. CIO Matt Griffiths, who joined the company from Dell shortly after Ms. Karaboutis, left the firm after just over a year in the position. Mr. Griffiths now holds a senior IT role at Stanley Black & Decker Inc.

After joining Biogen, Ms. Karaboutis told CIO Journal she found a mismatch between the structure of the company’s existing technology organization and the business goals of then-CEO Mr. Scangos and the board of directors, who wanted to see the company use emerging technologies to break into new businesses.

She broke Biogen’s technology group into three parts: one core team serving internal operations, and two new groups focused on data analytics and digital health using emerging technologies.

In an interview with CIO Journal last year, she noted that the company was looking to speed up the drug development process. For an IT project “that a few years back would take two years, I’m looking at six to eight months and 90-day deliverables within that,” she said. “It’s a much tighter cycle.”

Biogen’s profit slid 22% in the latest quarter as it booked charges related to its multiple sclerosis drug Tecfidera, and revenue grew less than expected.

The company reported net income of $649.2 million, down from $831.6 million in the year-ago fourth quarter. Revenue rose 1% to $2.87 billion, less than the $2.94 billion analysts anticipated.